Drug Profile
Research programme: cardiovascular disorder endothelial cell therapy - Takeda
Alternative Names: PVS-10300Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Pervasis Therapeutics
- Developer Shire
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 19 Apr 2012 Shire acquires all the assets of Pervasis Therapeutics